Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174015 | 0.87 | PIK3CD (0.35) | CLK4ALOX15LMNAHTTPIK3CD | |
| SCHEMBL12006061 | 0.85 | PIK3CD (0.41) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4173754 | 0.83 | LMNA (0.41) | ALDH1A1TSHRCLK4ALOX15LMNA | |
| SCHEMBL4178120 | 0.83 | PIK3CD (0.47) | CYP3A4CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL4173814 | 0.83 | PIK3CD (0.38) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4174503 | 0.82 | LMNA (0.39) | ALOX15LMNAHTTPIK3CDAURKA | |
| SCHEMBL4178542 | 0.81 | PIK3CD (0.40) | CLK4ALOX15LMNAHTTPIK3CD | |
| SCHEMBL12004308 | 0.81 | PIK3CD (0.39) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4169478 | 0.81 | PIK3CD (0.43) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL12004919 | 0.80 | PIK3CD (0.41) | ALOX15LMNAHTTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | CYP3A4 3267/4885CYP2C19 2228/4885CYP1A2 2390/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | CYP3A4 3267/4885CYP2C19 2228/4885CYP1A2 2390/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | CYP3A4 3267/4885CYP2C19 2228/4885CYP1A2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.